Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.70 |
| ▸ | ANPEP | P15144 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13937654 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13494285 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL15482322 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL20215871 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13841888 | 1.00 | MMP2 (0.70) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL19898335 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13868207 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL25594421 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL26967475 | 0.89 | MMP2 (0.54) | MMP2ANPEPCYP1A2POLBCYP3A4 | |
| SCHEMBL13962503 | 0.88 | MMP2 (0.56) | MMP2ANPEPPOLBNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472149-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222915-A1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-2776409-B1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS CORP (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2014-10-16 | — | — | US | disclosed |
| EP-2537845-B1 | 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2537845-A1 | 6H-dibenzo[B,E]oxepine derived nonsteroidal mineralocorticoid receptor antagonists | Eli Lilly and Company (US) | 2012-12-26 | — | — | EP | disclosed |
| US-7994164-B2 | Mineralocorticoid receptor antagonists and methods of use | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| WO-2009085584-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163472-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE | NR3C2, MC2R, REN | MMP2 2015/4885ANPEP 2686/4885CYP1A2 806/4885 |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | API5, BIRC5, BAD | MMP2 2035/4885ANPEP 1414/4885CYP1A2 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.